proactiveinvestors.co.uk · Dec 8, 2025
Puretech gains after FDA meeting post-Phase II trial
PureTech Health (LSE:PRTC, NASDAQ:PRTC, OTC:PTCHF) shares rose 4.9% to 128p on Wednesday after the company said it had completed a successful end-of-Phase 2 meeting with the US Food and Drug Administration for deupirfenidone, its lead idiopathic pulmonary fibrosis candidate. The regulator's feedback supports advancement into a pivotal Phase 3 trial and confirms the suitability of the streamlined 505(b)(2) regulatory pathway, reducing a major point of uncertainty around the programme.
